Accessibility Menu
PharmAust logo

PharmAust(ASX) PAA

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)-99%
5 Year-31%
1 Year-64%
1 Month-6%
N/A
PharmAust last closing stock price
MetricPriceDate
Last closeAUD 0.062026-08-14
PharmAust stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.59%AUD 0.062026-08-07
1 month-6.06%AUD 0.072026-07-15
3 month-13.89%AUD 0.072026-05-15
Year to date-27.06%AUD 0.092025-12-31
1 year-63.53%AUD 0.172025-08-14
3 year-15.07%AUD 0.072023-08-15
5 year-31.11%AUD 0.092021-08-13
Since inception-99.08%AUD 6.732001-10-05

PharmAust Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.68M

Net Income (TTM)

-A$13.90M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 30, 2024

PAA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmAust

PharmAust Limited is an international biotechnology company focused on developing targeted cancer treatments for both human and animal applications. The company is engaged in drug discovery and holds a promising pipeline, including its primary therapeutic candidate, Monepantel (MPL), currently in Phase II clinical trials.

Products and Services
  • Development of targeted cancer treatments for humans and animals
  • Intellectual property cultivation in drug discovery
  • Synthetic and medicinal chemistry products and services
Growth Outlook
  • Ongoing Phase II trials for Monepantel may lead to significant advancements
  • Research collaboration with the Walter and Eliza Hall Institute enhances credibility
  • Expansion into international markets, including Switzerland and the U.S.
Financial Highlights
  • Recent quarterly revenue of AUD 857,347, showing potential for growth
  • Cash and cash equivalents increased to AUD 9.71 million as of June 2024
  • Current ratio of 2.84 indicates strong liquidity position
PharmAust Limited operates in a dynamic sector with a focus on innovative cancer therapies. The company's commitment to research and development is evident through its ongoing clinical trials and strategic partnerships. The recent financial data reflects a solid cash position, which may support future growth initiatives. With a focus on expanding its market presence and advancing its therapeutic candidates, PharmAust presents an intriguing opportunity for investors interested in the biotechnology field.
AI Generated • Jul 23, 2026

Industry

Pharmaceuticals

CEO

Michael Thurn, PhD

Headquarters

Bentley, WA 6102, AU

PAA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-254.33%

Return on Capital

-65.10%

Return on Assets

-380.70%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-A$73.83K

Operating Income

-A$10.28M

EBITDA

-A$15.91M

Operating Cash Flow

-A$6.73M

Capital Expenditure

-A$34.93K

Free Cash Flow

-A$6.77M

Cash & ST Invst.

A$9.72M

Total Debt

A$0.00

PharmAust Performance Analysis

PharmAust annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 3,381,273N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
PharmAust sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-3112.6%
Q42023-06-30-52.5%
Q22023-12-31-5.7%
Q42024-06-30-100.0%
PharmAust annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.02258.5%
20242024-06-30AUD -0.0226.3%
20252025-06-30AUD -0.0339.6%
PharmAust sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22022-12-3193.3%
Q42023-06-30-19200.0%
Q22023-12-3194.3%
Q42024-06-30-1390.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$1.64K

-195.4%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

52

N/A

Net Income

-A$7.30M

-1417.8%

EBITDA

-A$7.29M

-2426.0%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

A$9.72M

+301.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$146.01K

-28.5%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-3.81%

N/A

Return on Invested Capital

-6.54%

N/A

Free Cash Flow

-A$5.12M

-1498.1%

Operating Cash Flow

-A$5.12M

-1189.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LV1.AXLive Verdure Ltd
A$0.92+0.00%
BNO.AXBionomics Limited
A$0.01-10.00%
MDC.AXMedlab Clinical Limited
A$6.60+0.00%
HXL.AXHexima Limited
A$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About PAA

What is the current price of PharmAust?

PharmAust is trading at N/A per share.

What is the 52-week range for PharmAust?

Over the past 52 weeks, PharmAust has traded between N/A and N/A.

How much debt does PharmAust have?

As of the most recent reporting period, PharmAust reported total debt of A$0.00.

How much cash does PharmAust have on hand?

PharmAust reported A$4.16M in cash and cash equivalents in its most recent financial results.

What is PharmAust’s dividend yield?

PharmAust does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.